Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

According to the study, which was published Monday in Nature Medicine, researchers found that use of the new medicines may ... Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ... a lot of weight could put them at risk for that disease, but a new study suggests that could indeed be the case. According to a recent study ...

A new study suggests belly fat could increase the ... Weight loss drugs such as Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) could be crucial treatment options for patients looking to keep ...

Last year, the medicine aced a phase 3 study in which it delayed ... including several new ones. Over the past two years, Eli Lilly has earned approval for such products as Alzheimer's disease ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...